Company intelligence / Profile preview

Xiushi Biopharma

Nantong City, Jiangsu Province, China

Ownership: Private
Development stage: Other

Overview

Xiushi Biopharma has established itself as a leading international CDMO specializing in large-scale biosynthesis of polypeptide drugs. The company provides comprehensive solutions from early research through clinical development to commercial manufacturing. It has developed the world’s first biosynthetic complex cyclic peptide drug technology platform and has entered into commercial partnerships for innovative diabetes treatments. The company completed a significant pre-A round financing in early 2024.

Therapeutic areas: Endocrinology
Modalities: PeptidesOligonucleotidesSmall molecule
Industry: Contract Manufacturing Organization

Partnerships

Commercial cooperation with an ultra long-term diabetes treatment innovative drug project partner (details undisclosed)

Beyond the preview

Go deeper on Xiushi Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiushi Biopharma.

Explore the full profile